Back to results
US 2014/0228419 A1Published application
Novel Isocyanate And Isothiocyanate Compounds For Cancer Treatment
AssigneeDoubleHill GmbH
InventorsJochen Kalbe, Olaf Hansen
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel isocyanate and isothiocyanate compounds, to pharmaceutical compositions comprising them, and to the use thereof in the treatment of cancer diseases in humans and animals. The novel isocyanate and isothiocyanate compounds are distinguished, as compared with the known isocyanate and isothiocyanate compounds, by improved therapeutical breadth, i.e. fewer side effects while having high anti-tumor activity.
Claims21
1-11. (canceled)
Compounds of the formula (1):
- wherein
- Y1═S or O and wherein
- R1, R2, R3, R4, R5, R6, R7 and R8 are identical or different and are in each case selected from the group consisting of:
- hydrogen,
- hydroxy,
- halogen,
- cyano,
- nitro,
- carboxyl,
- aminocarbonyl,
- sulfonic acid radical (—SO3H),
- aminosulfonyl,
- optionally substituted alkyl,
- optionally substituted alkoxy,
- optionally substituted alkenyl,
- optionally substituted aryl,
- optionally substituted alkylaryl;
- R9 is optionally substituted linear, branched or cyclic alkenediyl, optionally substituted linear, branched or cyclic alkenediyl, aryl or heterocyclyl;
- Z1 is selected from
- hydroxy (—OH) or
- a radical of the formula-N—R10R11, wherein
- R10 is hydrogen and R11 is optionally substituted alkyl or hydroxyl, or
- R11 is hydrogen and R10 optionally substituted alkyl or hydroxyl, or
- R10 and R11 are each alkyl, wherein at least one of the alkyl groups has at least one substituent, or
- R10 and R11, together with the nitrogen atom to which they are bonded, form a saturated or unsaturated, optionally substituted 5- to 8-membered ring which can optionally contain further heteroatoms;
- and wherein
- X1 is selected from the group consisting of:
- a single bond,
- carbonyl,
- sulfur,
- oxygen,
- sulfoxy,
- sulfonyl,
- azo and
- an optionally substituted, saturated or unsaturated aliphatic radical having from 1 to 6 carbon atoms,
- or pharmaceutically acceptable salts thereof.
33 more elements
A method of treating cancer, comprising administering to a patient in need thereof, compounds of the formula (1):
- wherein
- Y1═S or O and wherein
- R1, R2, R3, R4, R5, R6, R7 and R8 are identical or different and are in each case selected from the group consisting of:
- hydrogen,
- hydroxy,
- halogen,
- cyano,
- nitro,
- carboxyl,
- aminocarbonyl,
- sulfonic acid radical (—SO3H),
- aminosulfonyl,
- optionally substituted alkyl,
- optionally substituted alkoxy,
- optionally substituted alkenyl,
- optionally substituted aryl,
- optionally substituted alkylaryl;
- R9 is optionally substituted linear, branched or cyclic alkanediyl, optionally substituted linear, branched or cyclic alkenediyl, aryl or heterocyclyl;
- Z1 is selected from
- hydroxy (—OH) or
- a radical of the formula-N—R10R11, wherein
- R10 is hydrogen and R11 is optionally substituted alkyl or hydroxyl, or
- R11 is hydrogen and R10 optionally substituted alkyl or hydroxyl, or
- R10 and R11 are each alkyl, wherein at least one of the alkyl groups has at least one substituent, or
- R10 and R11, together with the nitrogen atom to which they are bonded, form a saturated or unsaturated, optionally substituted 5- to 8-membered ring which can optionally contain further heteroatoms;
- and wherein
- X1 is selected from the group consisting of:
- a single bond,
- carbonyl,
- sulfur,
- oxygen,
- sulfoxy,
- sulfonyl,
- azo and
- an optionally substituted, saturated or unsaturated aliphatic radical having from 1 to 6 carbon atoms,
- or pharmaceutically acceptable salts thereof.
33 more elements
Dependencies are inferred from the claim text.